Aerovate Therapeutics, Inc. (AVTE)

Aerovate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	33.75	23.49	22.4	54.2	4.57
Short-Term Investments	44.87	98.95	106.82	113.18	-
Cash & Short-Term Investments	78.62	122.44	129.22	167.38	4.57
Cash Growth	-35.79%	-5.25%	-22.80%	3560.07%	30.14%
Prepaid Expenses	0.65	1.54	1.98	6.72	0.07
Other Current Assets	0.85	0.25	0.3	0.24	0.04
Total Current Assets	80.12	124.23	131.5	174.33	4.68
Property, Plant & Equipment	0.22	0.9	1.25	0.73	0.04
Other Long-Term Assets	-	2.28	2.56	0.3	-
Total Assets	80.33	127.42	135.3	175.36	4.72
Accounts Payable	0.22	2.4	2.58	1.21	0.61
Accrued Expenses	2.87	13.73	4.44	1.01	1.14
Current Portion of Leases	0.42	0.42	0.39	0.19	-
Other Current Liabilities	0.32	1.09	0.38	0.14	0.02
Total Current Liabilities	3.83	17.64	7.78	2.55	1.77
Long-Term Leases	-	0.26	0.71	0.38	-
Other Long-Term Liabilities	0.07	0.07	0.07	0.01	-
Total Liabilities	3.9	17.96	8.56	2.95	1.77
Common Stock	0	0	0	0	-
Additional Paid-In Capital	309.38	272.64	215.11	208.87	0.06
Retained Earnings	-233.05	-163.42	-87.9	-36.39	-13.41
Comprehensive Income & Other	0.11	0.24	-0.47	-0.06	-
Total Common Equity	76.43	109.46	126.74	172.42	-13.34
Shareholders' Equity	76.43	109.46	126.74	172.42	2.94
Total Liabilities & Equity	80.33	127.42	135.3	175.36	4.72
Total Debt	0.42	0.68	1.09	0.57	-
Net Cash (Debt)	78.21	121.76	128.13	166.8	4.57
Net Cash Growth	-35.77%	-4.97%	-23.18%	3547.52%	350.99%
Net Cash Per Share	2.74	4.62	5.24	13.57	18.88
Filing Date Shares Outstanding	28.99	27.86	24.81	24.41	0.24
Total Common Shares Outstanding	28.99	27.76	24.72	24.41	0.24
Working Capital	76.29	106.6	123.71	171.78	2.9
Book Value Per Share	2.64	3.94	5.13	7.06	-54.90
Tangible Book Value	76.43	109.46	126.74	172.42	-13.34
Tangible Book Value Per Share	2.64	3.94	5.13	7.06	-54.90

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q